{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:40:06Z","timestamp":1786977606213,"version":"build-2736575974"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1474,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Projekt DEAL"},{"name":"OMRON Healthcare, Co, Ltd, Kyoto, Japan"},{"name":"European Research Area Net for Cardiovascular Diseases","award":["JTC2017-046-PROACT"],"award-info":[{"award-number":["JTC2017-046-PROACT"]}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["713601-uPROPHET"],"award-info":[{"award-number":["713601-uPROPHET"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["2011-294713-EPLORE"],"award-info":[{"award-number":["2011-294713-EPLORE"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["HEALTH-F7-305507 HOMAGE"],"award-info":[{"award-number":["HEALTH-F7-305507 HOMAGE"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["713601\u2010uPROPHET"],"award-info":[{"award-number":["713601\u2010uPROPHET"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["2011\u2010294713\u2010EPLORE"],"award-info":[{"award-number":["2011\u2010294713\u2010EPLORE"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH\u2010F7\u2010305507 HOMAGE"],"award-info":[{"award-number":["HEALTH\u2010F7\u2010305507 HOMAGE"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Recent trials evaluating the effect of aspirin in the primary prevention of cardiovascular disease showed little or no benefit. However, the role of aspirin on the risk of incident heart failure (HF) remains elusive. This study aimed to evaluate the role of aspirin use on HF incidence in primary and secondary prevention and whether aspirin use increases the risk of incident HF in patients at risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Data from 30 827 patients at risk for HF enrolled in six observational studies were analysed [women 33.9%, mean age (\u00b1standard deviation) 66.8 \u00b1 9.2 years]. Cardiovascular risk factors and aspirin use were recorded at baseline, and patients were followed up for the first incident of fatal or non-fatal HF. The association of incident HF with aspirin use was assessed using multivariable-adjusted proportional hazard regression, which accounted for study and cardiovascular risk factors. Over 5.3 years (median; 5th\u201395th percentile interval, 2.1\u201311.7 years), 1330 patients experienced HF. The fully adjusted hazard ratio (HR) associated with aspirin use was 1.26 [95% confidence interval (CI) 1.12\u20131.41; P \u2264 0.001]. Further, in a propensity-score-matched analysis, the HR was 1.26 (95% CI 1.10\u20131.44; P \u2264 0.001). In 22 690 patients (73.6%) without history of cardiovascular disease, the HR was 1.27 (95% CI 1.10\u20131.46; P = 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients, at risk, aspirin use was associated with incident HF, independent of other risk factors. In the absence of conclusive trial evidence, our observations suggest that aspirins should be prescribed with caution in patients at risk of HF or having HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13688","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T19:09:00Z","timestamp":1637608140000},"page":"685-694","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Aspirin Use is Associated with Increased Risk for Incident Heart Failure: A Patient-Level Pooled Analysis"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5831-0800","authenticated-orcid":false,"given":"Blerim","family":"Mujaj","sequence":"first","affiliation":[{"name":"Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven , Leuven ,","place":["Belgium"]},{"name":"Department of Diagnostic and Interventional Radiology, University Centre, Faculty of Medicine, University of Freiburg , Freiburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3785-7417","authenticated-orcid":false,"given":"Zhen-Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-0866","authenticated-orcid":false,"given":"Wen-Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8108-2356","authenticated-orcid":false,"given":"Lutgarde","family":"Thijs","sequence":"additional","affiliation":[{"name":"Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9135-1660","authenticated-orcid":false,"given":"Fang-Fei","family":"Wei","sequence":"additional","affiliation":[{"name":"Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8698-2858","authenticated-orcid":false,"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[{"name":"Centre for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences, University of Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-2612","authenticated-orcid":false,"given":"Christian","family":"Delles","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Centre , Jackson, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0421-2409","authenticated-orcid":false,"given":"Peter","family":"Sever","sequence":"additional","affiliation":[{"name":"International Centre for Circulatory Health and National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-4650","authenticated-orcid":false,"given":"Roberto","family":"Latini","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, IRCCS \u2013 Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-7016","authenticated-orcid":false,"given":"John","family":"GF Cleland","sequence":"additional","affiliation":[{"name":"Cardiology Department, Castle Hill Hospital, University of Hull and Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"INSERM, Centre d'Investigations Cliniques Plurithe'matique 1433, INSERM U1116, CHRU de Nancy, F-CRIN INI-CRCT, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3026-1637","authenticated-orcid":false,"given":"Jan A.","family":"Staessen","sequence":"additional","affiliation":[{"name":"Research Institute Alliance for the Promotion of Preventive Medicine (APPREMED) , Mechelen ,","place":["Belgium"]},{"name":"Biomedical Science Group, University of Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Heart Omics in Ageing Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"2026012114181745700_ehf213688-bib-0001","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failureThe task force for the diagnosis and treatment of acute and chronic heart failure of the european Society of Cardiology (ESC)Developed with the special contribution of the heart failure association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114181745700_ehf213688-bib-0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005231","article-title":"Risk for incident heart failure: A subject-level meta-analysis from the heart \"OMics\" in AGEing (HOMAGE) study","volume":"6","author":"Jacobs","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026012114181745700_ehf213688-bib-0003","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm","volume":"366","author":"Homma","year":"2012","journal-title":"N Engl J Med"},{"key":"2026012114181745700_ehf213688-bib-0004","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practiceThe Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J."},{"key":"2026012114181745700_ehf213688-bib-0005","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"New England J Med."},{"key":"2026012114181745700_ehf213688-bib-0006","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet (London, England)."},{"key":"2026012114181745700_ehf213688-bib-0007","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114181745700_ehf213688-bib-0008","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet."},{"key":"2026012114181745700_ehf213688-bib-0009","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/CIRCULATIONAHA.108.801753","article-title":"Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: The warfarin and antiplatelet therapy in chronic heart failure (WATCH) trial","volume":"119","author":"Massie","year":"2009","journal-title":"Circulation"},{"key":"2026012114181745700_ehf213688-bib-0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The Warfarin\/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure","volume":"148","author":"Cleland","year":"2004","journal-title":"Am Heart J."},{"key":"2026012114181745700_ehf213688-bib-0011","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/CIRCHEARTFAILURE.113.000132","article-title":"Aspirin use in heart failure: Is low-dose therapy associated with mortality and morbidity benefits in a large community population?","volume":"7","author":"Bermingham","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026012114181745700_ehf213688-bib-0012","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jchf.2017.09.021","article-title":"Low-dose aspirin in heart failure not complicated by atrial fibrillation: A Nationwide propensity-matched study","volume":"6","author":"Madelaire","year":"2018","journal-title":"JACC Heart Fail."},{"key":"2026012114181745700_ehf213688-bib-0013","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1093\/eurheartj\/eht287","article-title":"Is aspirin useful in primary prevention?","volume":"34","author":"Cleland","year":"2013","journal-title":"Eur Heart J"},{"key":"2026012114181745700_ehf213688-bib-0014","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA."},{"key":"2026012114181745700_ehf213688-bib-0015","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7555\/JBR.28.20140045","article-title":"Heart \u2018omics\u2019 in AGEing (HOMAGE): Design, research objectives and characteristics of the common database","volume":"28","author":"Jacobs","year":"2014","journal-title":"J Biomed Res"},{"key":"2026012114181745700_ehf213688-bib-0016","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200106000-00020","article-title":"Rationale, design, methods and baseline demography of participants of the anglo-scandinavian cardiac outcomes trial","volume":"19","author":"Sever","year":"2001","journal-title":"ASCOT investigators. J Hypertens."},{"key":"2026012114181745700_ehf213688-bib-0017","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/00004872-200108000-00002","article-title":"Effects of three candidate genes on prevalence and incidence of hypertension in a caucasian population","volume":"19","author":"Staessen","year":"2001","journal-title":"J Hypertens"},{"key":"2026012114181745700_ehf213688-bib-0018","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/archinternmed.2009.40","article-title":"Epidemiology of incident heart failure in a contemporary elderly cohort: The health, aging, and body composition study","volume":"169","author":"Kalogeropoulos","year":"2009","journal-title":"Arch Intern Med"},{"key":"2026012114181745700_ehf213688-bib-0019","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurjhf\/hft098","article-title":"Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from \u2018PREDICTOR\u2019, a population based-study in Central Italy","volume":"15","author":"Mureddu","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026012114181745700_ehf213688-bib-0020","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0002-9149(99)00533-0","article-title":"The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk","volume":"84","author":"Shepherd","year":"1999","journal-title":"Am J Cardiol."},{"key":"2026012114181745700_ehf213688-bib-0021","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2026012114181745700_ehf213688-bib-0022","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: Analysis of individual patient data from randomised trials","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet (London, England)."},{"key":"2026012114181745700_ehf213688-bib-0023","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: A report of the american College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"2026012114181745700_ehf213688-bib-0024","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of Aspirin use for primary prevention with cardiovascular events and bleeding events: A systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"2026012114181745700_ehf213688-bib-0025","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0140-6736(19)30541-0","article-title":"The rise and fall of aspirin in the primary prevention of cardiovascular disease","volume":"393","author":"Raber","year":"2019","journal-title":"Lancet."},{"key":"2026012114181745700_ehf213688-bib-0026","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.120.045695","article-title":"Lifelong aspirin for all in the secondary prevention of chronic coronary syndrome: still sacrosanct or is reappraisal warranted?","volume":"142","author":"Jacobsen","year":"2020","journal-title":"Circulation."},{"key":"2026012114181745700_ehf213688-bib-0027","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.120.045695","article-title":"Lifelong aspirin for all in the secondary prevention of chronic coronary syndrome","volume":"142","author":"Jacobsen","year":"2020","journal-title":"Circulation."},{"key":"2026012114181745700_ehf213688-bib-0028","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"New England Journal of Medicine."},{"key":"2026012114181745700_ehf213688-bib-0029","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2019.9811","article-title":"Association of Office and Ambulatory Blood Pressure with Mortality and cardiovascular outcomes","volume":"322","author":"Yang","year":"2019","journal-title":"JAMA"},{"key":"2026012114181745700_ehf213688-bib-0030","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1600177","article-title":"Blood-pressure and cholesterol lowering in persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"New England Journal of Medicine."},{"key":"2026012114181745700_ehf213688-bib-0031","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114181745700_ehf213688-bib-0032","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension."},{"key":"2026012114181745700_ehf213688-bib-0033","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11906-014-0447-7","article-title":"Hypertension as a risk factor for heart failure","volume":"16","author":"Kannan","year":"2014","journal-title":"Curr Hypertens Rep"},{"key":"2026012114181745700_ehf213688-bib-0034","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/erc.10.27","article-title":"Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics","volume":"8","author":"Duarte","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026012114181745700_ehf213688-bib-0035","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0002-9343(03)00436-4","article-title":"Early and late effects of low-dose aspirin on renal function in elderly patients","volume":"115","author":"Segal","year":"2003","journal-title":"Am J Med"},{"key":"2026012114181745700_ehf213688-bib-0036","first-page":"679","article-title":"Renal effects of low dose aspirin in elderly patients","volume":"8","author":"Segal","year":"2006","journal-title":"Isr Med Assoc J"},{"key":"2026012114181745700_ehf213688-bib-0037","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1093\/eurheartj\/ehy433","article-title":"Antithrombotic treatment is associated with intraplaque haemorrhage in the atherosclerotic carotid artery: a cross-sectional analysis of The Rotterdam Study","volume":"39","author":"Mujaj","year":"2018","journal-title":"Eur Heart J."},{"key":"2026012114181745700_ehf213688-bib-0038","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jacc.2021.01.038","article-title":"Atherosclerotic carotid plaque composition and incident stroke and coronary events","volume":"77","author":"Bos","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"2026012114181745700_ehf213688-bib-0039","first-page":"237","article-title":"Aspirin for heart failure","volume":"7","author":"Cleland","year":"2014","journal-title":"Circulation: Heart Fail"},{"key":"2026012114181745700_ehf213688-bib-0040","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.amjcard.2006.01.107","article-title":"Anemia, renal dysfunction, and their interaction in patients with chronic heart failure","volume":"98","author":"de Silva","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026012114181745700_ehf213688-bib-0041","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.326.7380.82","article-title":"Platelet responsiveness to aspirin in patients with hyperlipidaemia","volume":"326","author":"Friend","year":"2003","journal-title":"BMJ"},{"key":"2026012114181745700_ehf213688-bib-0042","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0167-5273(02)00195-X","article-title":"Beyond lipid lowering: The role of statins in vascular protection","volume":"86","author":"Liao","year":"2002","journal-title":"Int J Cardiol"},{"key":"2026012114181745700_ehf213688-bib-0043","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1745-6215-8-21","article-title":"Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): Design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins","volume":"8","author":"De Berardis","year":"2007","journal-title":"Trials"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13688","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13688","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/1\/685\/65375200\/eschf_9_1_685.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/1\/685\/65375200\/eschf_9_1_685.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:21:38Z","timestamp":1769023298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/1\/685\/8326341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,11,22]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13688","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2]]},"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"2021-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}